Hematological Malignancies

Immunotherapy of malignant lymphoma

• R-chemo SoC in most B-cell lymphoma including DLBCL and low-grade lymphoma • MoAb-based maintenance established in low grades and cHL; role of maintenance in DLBCL unclear • Anti-PD1 moabs extremely promising, mainly in HL • Immunotherapy might at least in part replace chemo- and radiotherapy in the future